About all

Aminoglycosides antibiotics list. Aminoglycoside Antibiotics: A Comprehensive Guide to Usage, Efficacy, and Safety

What are the key characteristics of aminoglycoside antibiotics. How do aminoglycosides work against bacterial infections. What are the main indications for using aminoglycoside antibiotics in clinical practice. How should aminoglycoside dosing be optimized for maximum efficacy and safety. What are the potential side effects and toxicities associated with aminoglycoside use. How can therapeutic drug monitoring improve aminoglycoside therapy. What are the emerging trends and future directions in aminoglycoside antibiotic development.

The Fundamentals of Aminoglycoside Antibiotics

Aminoglycosides are a class of broad-spectrum, bactericidal antibiotics that play a crucial role in treating various bacterial infections, particularly those caused by Gram-negative pathogens. These antibiotics have been a cornerstone of antimicrobial therapy for decades, owing to their potent activity against a wide range of bacteria.

The most commonly used aminoglycosides include:

  • Gentamicin
  • Amikacin
  • Tobramycin
  • Neomycin
  • Streptomycin

Among these, gentamicin stands out as the most frequently prescribed aminoglycoside in UK neonatal units, highlighting its significance in pediatric care.

How do aminoglycosides exert their antimicrobial effects? These antibiotics work by binding to the 30S subunit of bacterial ribosomes, thereby interfering with protein synthesis. This mechanism of action leads to rapid bacterial cell death, making aminoglycosides highly effective against susceptible pathogens.

Pharmacokinetics and Administration of Aminoglycosides

Understanding the pharmacokinetics of aminoglycosides is crucial for their safe and effective use. These antibiotics exhibit unique characteristics that influence their administration and dosing strategies:

  • Poor oral bioavailability: Aminoglycosides are polar molecules with limited gastrointestinal absorption.
  • Parenteral administration: Intravenous or intramuscular routes are typically used for systemic infections.
  • Renal excretion: The kidneys primarily eliminate aminoglycosides, making renal function a critical factor in dosing decisions.

Why are aminoglycosides considered concentration-dependent antibiotics? The ratio of peak concentration to the minimum inhibitory concentration (MIC) of the target pathogen is the key pharmacokinetic-pharmacodynamic index associated with their antimicrobial activity and clinical efficacy. This characteristic influences dosing strategies, often favoring once-daily dosing regimens in appropriate clinical scenarios.

Optimizing Aminoglycoside Dosing

To maximize the therapeutic benefits of aminoglycosides while minimizing toxicity risks, clinicians must carefully consider several factors:

  1. Patient age and weight
  2. Renal function
  3. Site and severity of infection
  4. Concomitant medications
  5. Pathogen susceptibility

How can dosing be optimized for different patient populations? In neonates and young children, weight-based dosing is typically employed, with adjustments made based on gestational and postnatal age. For adults, dosing may be based on ideal body weight or adjusted body weight, depending on the specific aminoglycoside and institutional protocols.

Therapeutic Applications of Aminoglycosides

Aminoglycosides are valuable antimicrobial agents in various clinical settings. Their broad spectrum of activity makes them particularly useful for treating severe infections caused by Gram-negative bacteria. Common indications for aminoglycoside therapy include:

  • Sepsis and bacteremia
  • Nosocomial pneumonia
  • Complicated urinary tract infections
  • Intra-abdominal infections
  • Endocarditis (in combination with other antibiotics)

In pediatric practice, gentamicin is frequently used as empiric therapy for neonatal sepsis, often in combination with a beta-lactam antibiotic to provide synergistic activity and broader coverage.

Why are aminoglycosides often used in combination with other antibiotics? Combination therapy can offer several advantages:

  1. Synergistic effects against certain pathogens
  2. Broader spectrum of coverage
  3. Potential reduction in the emergence of resistance
  4. Lower doses of individual agents, potentially reducing toxicity risks

Monitoring and Managing Aminoglycoside Therapy

Due to their narrow therapeutic index, careful monitoring is essential when using aminoglycosides. Therapeutic drug monitoring (TDM) plays a crucial role in optimizing efficacy while minimizing the risk of adverse effects.

Therapeutic Drug Monitoring Strategies

How is therapeutic drug monitoring performed for aminoglycosides? TDM typically involves measuring serum drug concentrations at specific time points:

  • Peak levels: Measured shortly after dose administration to ensure adequate drug concentrations are achieved
  • Trough levels: Measured just before the next dose to assess drug clearance and minimize toxicity risks

Interpreting these levels in conjunction with clinical response and microbiological data allows for individualized dose adjustments, ensuring optimal therapeutic outcomes.

Renal Function Monitoring

Why is monitoring renal function crucial during aminoglycoside therapy? Aminoglycosides are primarily excreted by the kidneys and can cause nephrotoxicity. Regular assessment of renal function through serum creatinine measurements and estimated glomerular filtration rate (eGFR) calculations is essential to detect early signs of kidney injury and guide dosing adjustments.

Potential Adverse Effects and Toxicities

While aminoglycosides are highly effective antibiotics, they are associated with significant potential toxicities that require careful consideration and monitoring:

Nephrotoxicity

How does aminoglycoside-induced nephrotoxicity manifest? Renal toxicity typically presents as acute kidney injury, characterized by:

  • Elevated serum creatinine
  • Decreased urine output
  • Electrolyte imbalances

Risk factors for nephrotoxicity include prolonged therapy, high drug concentrations, concurrent nephrotoxic medications, and pre-existing renal impairment.

Ototoxicity

Aminoglycosides can cause irreversible damage to the inner ear, leading to hearing loss and vestibular dysfunction. What are the key aspects of aminoglycoside-induced ototoxicity?

  • Can affect both auditory and vestibular functions
  • May be irreversible
  • Risk increases with prolonged therapy and higher cumulative doses
  • Genetic factors may predispose certain individuals to increased susceptibility

Regular audiometric testing and vigilance for symptoms such as tinnitus or balance disturbances are crucial for early detection of ototoxicity.

Neuromuscular Blockade

In rare cases, aminoglycosides can cause neuromuscular blockade, particularly when administered in high doses or in patients with underlying neuromuscular disorders. This effect can lead to respiratory muscle weakness and, in severe cases, respiratory failure.

Emerging Trends and Future Directions

Despite the challenges associated with their use, aminoglycosides remain important antibiotics in the fight against bacterial infections. Research continues to explore ways to enhance their efficacy and safety profile:

Novel Aminoglycoside Derivatives

What advancements are being made in aminoglycoside development? Researchers are working on new aminoglycoside derivatives with improved safety profiles and activity against resistant pathogens. These efforts aim to address the limitations of existing aminoglycosides while preserving their potent antimicrobial activity.

Targeted Drug Delivery Systems

Innovative drug delivery approaches are being explored to enhance the therapeutic index of aminoglycosides. These include:

  • Nanoparticle-based delivery systems
  • Liposomal formulations
  • Cochlear-targeted delivery for reducing ototoxicity

How might these novel delivery systems improve aminoglycoside therapy? By allowing for more precise targeting of infected tissues and reducing systemic exposure, these approaches have the potential to enhance efficacy while minimizing adverse effects.

Combination Therapies

Research into synergistic combinations of aminoglycosides with other antimicrobial agents continues to evolve. These strategies aim to:

  1. Overcome resistance mechanisms
  2. Reduce required doses of individual agents
  3. Expand the spectrum of activity

Promising combinations include aminoglycosides with beta-lactams, fluoroquinolones, and novel antimicrobial peptides.

Practical Considerations for Aminoglycoside Prescribing

When prescribing aminoglycosides, healthcare providers must carefully weigh the potential benefits against the risks. Several practical considerations can help optimize therapy:

Patient Selection

Which patients are most likely to benefit from aminoglycoside therapy? Aminoglycosides are particularly valuable in:

  • Severe infections caused by Gram-negative pathogens
  • Empiric therapy for suspected sepsis in neonates and critically ill patients
  • Situations where rapid bactericidal activity is crucial

However, caution is warranted in patients with pre-existing renal impairment, hearing loss, or those at high risk for drug-induced toxicities.

Dosing Strategies

How can dosing regimens be optimized to maximize efficacy and minimize toxicity? Several approaches have been developed:

  1. Once-daily dosing: Exploits the concentration-dependent killing and post-antibiotic effect of aminoglycosides
  2. Extended-interval dosing: Particularly useful in neonates and patients with altered pharmacokinetics
  3. Individualized pharmacokinetic dosing: Tailors therapy based on patient-specific parameters and drug level monitoring

The choice of dosing strategy should be based on patient characteristics, infection site, and institutional protocols.

Duration of Therapy

What factors influence the optimal duration of aminoglycoside therapy? Generally, aminoglycoside treatment should be as short as clinically appropriate to minimize toxicity risks. Factors to consider include:

  • Severity and site of infection
  • Clinical response
  • Availability of less toxic alternative antibiotics
  • Presence of deep-seated or difficult-to-treat infections

In many cases, short courses of 3-5 days may be sufficient, particularly when used in combination with other antibiotics.

Aminoglycosides in Special Populations

The use of aminoglycosides requires special consideration in certain patient populations due to unique pharmacokinetic and pharmacodynamic considerations:

Neonates and Infants

Why do neonates require careful dosing of aminoglycosides? Neonates have immature renal function and larger volumes of distribution, necessitating adjusted dosing strategies:

  • Extended-interval dosing is often employed
  • Dose adjustments based on gestational and postnatal age
  • Close monitoring of drug levels and renal function

Critically Ill Patients

How does critical illness affect aminoglycoside pharmacokinetics? Critically ill patients may exhibit altered drug disposition due to:

  1. Changes in volume of distribution
  2. Fluctuations in renal function
  3. Altered protein binding

These factors necessitate individualized dosing and frequent monitoring to ensure therapeutic efficacy and minimize toxicity risks.

Pregnant Women

What considerations are important when using aminoglycosides during pregnancy? While aminoglycosides can cross the placenta, their use may be necessary in certain severe infections. Key points include:

  • Potential risks of ototoxicity to the fetus
  • Altered maternal pharmacokinetics due to pregnancy-related physiological changes
  • Careful risk-benefit assessment and close monitoring if used

Antimicrobial Stewardship and Aminoglycoside Use

Aminoglycosides play a significant role in antimicrobial stewardship programs, which aim to optimize antibiotic use and combat antimicrobial resistance. How can aminoglycoside use be incorporated into stewardship efforts?

Appropriate Prescribing

Key principles for appropriate aminoglycoside prescribing include:

  • Reserving use for severe infections or when narrower-spectrum alternatives are unsuitable
  • Utilizing local antibiograms to guide empiric therapy
  • De-escalating to narrower-spectrum antibiotics when culture results are available
  • Implementing standardized protocols for dosing and monitoring

Resistance Monitoring

Regular surveillance of aminoglycoside resistance patterns is crucial for guiding empiric therapy and detecting emerging resistance trends. This involves:

  1. Tracking local resistance rates
  2. Monitoring for emerging resistance mechanisms
  3. Collaborating with microbiology laboratories for timely reporting of susceptibility data

Education and Guidelines

Ongoing education of healthcare providers and the development of institutional guidelines are essential components of aminoglycoside stewardship. These efforts should focus on:

  • Optimal dosing strategies
  • Appropriate indications for use
  • Proper monitoring techniques
  • Recognition and management of adverse effects

By implementing these stewardship principles, healthcare institutions can promote the judicious use of aminoglycosides, preserving their efficacy while minimizing the risks associated with their use.

What do I need to know about aminoglycoside antibiotics?

. 2017 Apr;102(2):89-93.

doi: 10.1136/archdischild-2015-309069.

Epub 2016 Aug 9.

Eva Germovsek 
1
, Charlotte I Barker 
1
 
2
, Mike Sharland 
2

Affiliations

Affiliations

  • 1 Inflammation, Infection and Rheumatology Section, UCL Institute of Child Health, London, UK.
  • 2 Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George’s, University of London, London, UK.
  • PMID:

    27506599

  • DOI:

    10. 1136/archdischild-2015-309069

Eva Germovsek et al.

Arch Dis Child Educ Pract Ed.

2017 Apr.

. 2017 Apr;102(2):89-93.

doi: 10.1136/archdischild-2015-309069.

Epub 2016 Aug 9.

Authors

Eva Germovsek 
1
, Charlotte I Barker 
1
 
2
, Mike Sharland 
2

Affiliations

  • 1 Inflammation, Infection and Rheumatology Section, UCL Institute of Child Health, London, UK.
  • 2 Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George’s, University of London, London, UK.
  • PMID:

    27506599

  • DOI:

    10.1136/archdischild-2015-309069

Abstract

The aminoglycosides are broad-spectrum, bactericidal antibiotics that are commonly prescribed for children, primarily for infections caused by Gram-negative pathogens. The aminoglycosides include gentamicin, amikacin, tobramycin, neomycin, and streptomycin. Gentamicin is the most commonly used antibiotic in UK neonatal units. Aminoglycosides are polar drugs, with poor gastrointestinal absorption, so intravenous or intramuscular administration is needed. They are excreted renally. Aminoglycosides are concentration-dependent antibiotics, meaning that the ratio of the peak concentration to the minimum inhibitory concentration of the pathogen is the pharmacokinetic-pharmacodynamic index best linked to their antimicrobial activity and clinical efficacy. However, due to their narrow therapeutic index, the patient’s renal function should be monitored to avoid toxicity, and therapeutic drug monitoring is often required. Here we provide a review of aminoglycosides, with a particular focus on gentamicin, considering their pharmacokinetics and pharmacodynamics, and also practical issues associated with prescribing these drugs in a paediatric clinical setting.


Keywords:

children; gentamicin; neonates; prescribing.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Similar articles

  • Antimicrobial agents–Part II. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, neomycin.

    Brewer NS.

    Brewer NS.
    Mayo Clin Proc. 1977 Nov;52(11):675-9.
    Mayo Clin Proc. 1977.

    PMID: 336988

    Review.

  • [Aminoglycosides in pediatrics].

    Schaad UB.

    Schaad UB.
    Schweiz Med Wochenschr Suppl. 1996;76:34S-38S.
    Schweiz Med Wochenschr Suppl. 1996.

    PMID: 8677417

    Review.
    German.

  • Aminoglycoside resistance rates, phenotypes, and mechanisms of Gram-negative bacteria from infected patients in upper Egypt.

    Gad GF, Mohamed HA, Ashour HM.

    Gad GF, et al.
    PLoS One. 2011 Feb 17;6(2):e17224. doi: 10.1371/journal.pone.0017224.
    PLoS One. 2011.

    PMID: 21359143
    Free PMC article.

  • New aminoglycoside antibiotics.

    Dozzo P, Moser HE.

    Dozzo P, et al.
    Expert Opin Ther Pat. 2010 Oct;20(10):1321-41. doi: 10.1517/13543776.2010.506189.
    Expert Opin Ther Pat. 2010.

    PMID: 20670208

    Review.

  • Drug therapy reviews: Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics–part 4: aminoglycosides.

    Barza M, Scheife RT.

    Barza M, et al.
    Am J Hosp Pharm. 1977 Jul;34(7):723-37.
    Am J Hosp Pharm. 1977.

    PMID: 407790

See all similar articles

Cited by

  • Quality indicators for appropriate antibiotic prescribing in urinary tract infections in children.

    Vazouras K, Jackson C, Folgori L, Anastasiou-Katsiardani A, Hsia Y, Basmaci R.

    Vazouras K, et al.
    BMC Infect Dis. 2023 Jun 12;23(1):400. doi: 10.1186/s12879-023-08356-z.
    BMC Infect Dis. 2023.

    PMID: 37308821
    Free PMC article.

    Review.

  • An interdisciplinary student-led multifaceted intervention addressing overuse of broad-spectrum antibiotics for patients with penicillin allergies.

    Banashefski B, Henson P, David N, Kok HT, Beerkens FJ, Shyu M, Linker AS, Tsega S, Dunn A, Fuller R.

    Banashefski B, et al.
    Antimicrob Resist Infect Control. 2023 Apr 15;12(1):34. doi: 10.1186/s13756-023-01232-0.
    Antimicrob Resist Infect Control. 2023.

    PMID: 37061722
    Free PMC article.

  • Predictive Performance of Population Pharmacokinetic Models for Amikacin in Term Neonates.

    Matcha S, Dillibatcha J, Raju AP, Chaudhari BB, Moorkoth S, Lewis LE, Mallayasamy S.

    Matcha S, et al.
    Paediatr Drugs. 2023 May;25(3):365-375. doi: 10.1007/s40272-023-00564-z. Epub 2023 Mar 21.
    Paediatr Drugs. 2023.

    PMID: 36943583
    Free PMC article.

  • Antimicrobial Natural Hydrogels in Biomedicine: Properties, Applications, and Challenges-A Concise Review.

    Kapusta O, Jarosz A, Stadnik K, Giannakoudakis DA, Barczyński B, Barczak M.

    Kapusta O, et al.
    Int J Mol Sci. 2023 Jan 22;24(3):2191. doi: 10.3390/ijms24032191.
    Int J Mol Sci. 2023.

    PMID: 36768513
    Free PMC article.

    Review.

  • Evaluation of pre-treated healthcare wastes during COVID-19 pandemic reveals pathogenic microbiota, antibiotics residues, and antibiotic resistance genes against beta-lactams.

    Siew SW, Musa SM, Sabri N’, Farida Asras MF, Ahmad HF.

    Siew SW, et al.
    Environ Res. 2023 Feb 15;219:115139. doi: 10.1016/j.envres.2022.115139. Epub 2022 Dec 22.
    Environ Res. 2023.

    PMID: 36565841
    Free PMC article.

See all “Cited by” articles

MeSH terms

Substances

Aminoglycoside Antibacterials | DrugBank Online

AmikacinAn aminoglycoside used to treat infections caused by more resistant strains of Gram negative bacteria and some Gram positive bacteria.
TobramycinAn aminoglycoside antibiotic used to treat cystic fibrosis-associated bacterial, lower respiratory tract, urinary tract, eye, skin, bone, and skin structure infections.
GentamicinAn aminoglycoside used to treat a wide variety of aerobic infections in the body.
NeomycinAn aminoglycoside antibiotic agent used orally and topically to treat a wide variety of infections in the body.
StreptomycinAn aminoglycoside antibiotic indicated to treat multi-drug resistant mycobacterium tuberculosis and various non-tuberculosis infections.
FramycetinAn aminoglycoside antibiotic used in various formulations and combinations with other agents to treat hemorrhoids, eye and ear infections, and to reduce nasal carriage of staphylococcus.
NetilmicinAn aminoglycoside used to treat a wide variety of infections in the body.
KanamycinAn aminoglycoside antibiotic agent used in the treatment of various infections caused by susceptible bacteria.
ParomomycinAn aminoglycoside antibiotic used in the treatment of acute and chronic intestinal amebiasis, and as an adjunct for the management of hepatic coma.
RibostamycinA broad spectrum aminoglycoside antibiotic on the list of WHO critical antimicrobials for human medicine.
GeneticinGeneticin (also known as G418) is an aminoglycoside antibiotic similar in structure to gentamicin B1, produced by Micromonospora rhodorangea. Geneticin blocks polypeptide synthesis by inhibiting the elongation step in both…
ApramycinAn aminoglycoside antibiotic for veterinary use that is used to treat infections in animals.
Gentamicin C1aNot Available
NeamineNot Available
ArbekacinArbekacin is used for the short term treatment of multi-resistant bacterial infections, such as methicillin-resistant Staphylococcus aureus (MRSA).
PuromycinPuromycin is an antibiotic that prevents bacterial protein translation. It is utilized as a selective agent in laboratory cell cultures. Puromycin is toxic to both prokaryotic and eukaryotic cells, resulting…
DihydrostreptomycinDihydrostreptomycin is an aminoglycoside antibiotic. In humans, the use of dihydrostreptomycin has been associated with ototoxicity. The FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin…
Hygromycin BHygromycin B is an aminoglycoside antibiotic produced by the bacterium Streptomyces hygroscopicus which kills bacteria, fungi and higher eukaryotic cells by inhibiting protein synthesis.
SisomicinSisomicin has been used in trials studying the treatment of Pyoderma.
PlazomicinAn aminoglycoside antibiotic used to treat complicated urinary tract infections.
DibekacinDibekacin is an aminoglycoside antibiotic marketed in Japan .
MicronomicinMicronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names Sagamicin and Luxomicina.
IsepamicinNot Annotated
BekanamycinAn aminoglycoside antibiotic indicated in the treatment of eye infections.
CapreomycinAn aminoglycoside antibiotic used as an adjunct drug in tuberculosis.
ColistinA polymyxin antibiotic used to treat bacterial infections caused by susceptible Gram negative bacteria.
Nanoparticle EpirubicinNanoparticle Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma). It is a novel epirubicin…
BerubicinNot Annotated
NC-6300NC-6300, also known as K-912, is a novel epirubicin drug-conjugated polymeric micelle.

List of drugs that contribute to the development of hearing impairment in the Hearing Studio

0

Expert

07.04.201601:4407.04.2016 01:44:36

Salicylates: aspirin and products containing aspirin

The ototoxic effect usually appears after taking an average of 6-8 tablets per day. After aspirin is eliminated from the body, the ototoxic effect almost always stops.

Non-steroidal anti-inflammatory drugs

Indomethacin, flurbiprofen, diclofenac sodium, piroxicam, ketoprofen, naproxen, ibuprofen, amidopyrine. This also includes paracetamol, although strictly speaking this drug does not belong to this group.

Toxic effects usually appear after consuming an average of 6-8 tablets per day. The toxic effect is usually reversible upon discontinuation of the drug.

Antibiotics: aminoglycosides, erythromycin, vancomycin

Aminoglycosides – streptomycin, kanamycin, neomycin, gentamicin, amikacin, netilmicin. These drugs exhibit ototoxic effects when administered intravenously in life-threatening situations. When applied topically, including in ear drops, these drugs do not show an ototoxic effect.

Erythromycin and its derivatives are generally ototoxic when administered intravenously at a dose of 2-4 g over 24 hours, especially in the presence of renal insufficiency. The usual oral dose of erythromycin, averaging one gram per 24 hours, is not harmful to the organs of the inner ear.

Vancomycin. This antibiotic is ototoxic in the same way as aminoglycosides when given intravenously for serious life-threatening infections. As a rule, in this case it is used in combination with aminoglycosides, which further increases the risk of damage to the auditory nerve.

Loop diuretics

Furosemide, bumetanide, ethacrynic acid, pyretanide, torasemide.

These drugs are ototoxic when administered intravenously in acute renal failure or acute hypertension. Rare cases of ototoxicity have been reported with high doses of these tablets in patients with chronic kidney disease.

Chemotherapy drugs

Cisplatin, nitrogen mustard, vincristine.

The ototoxic effect of these drugs is enhanced in patients who are also taking other ototoxic drugs such as aminoglycosides or loop diuretics.

Quinine and quinine preparations

Acrikhin muscle relaxants (for the treatment of nocturnal convulsions).

The ototoxic effect of quinine is very similar to that of aspirin, the toxic effect is usually reversible upon cessation of treatment.

Antidepressants
Although antidepressants are not strictly ototoxic, their use can cause or exacerbate tinnitus in some people. This effect is most pronounced in tricyclic antidepressants such as clomipramine and amitriptyline. Selective serotonin reuptake inhibitor (SSRI) antidepressants such as Prozac, Zoloft, Paxil, Fevarin can also cause tinnitus. People suffering from tinnitus are advised to use the antidepressant Remeron, which has not been shown to have an ototoxic effect.

Expert

04/07/201601:4404/07/2016 01:44:36

Hits:17454

0

Tags: deafness, drugs

Aminoglycosides :: Description of the group of drugs

Aminoglycosides (aminoglycoside aminocyclitols) are natural and semi-synthetic antibiotics containing aminosaccharide molecules linked to hexose by a glycosidic bond. Hexose is called streptidine (hence the name – streptomycin). Streptomycin is the first antibiotic of this group, was obtained in 1943 by the Zelman Waxman Research Group in the USA. Waksman was awarded the Nobel Prize in 1952 for this discovery. More than 10 natural antibiotics produced by radiant fungi Actinomyces (neomycin, kanamycin, tobramycin, etc.), Micromonospora (gentamicin, etc.) have been isolated. Semi-synthetic aminoglycosides are derived from natural ones (amikacin – obtained from kanamycin A). The same group includes the natural aminocyclitol antibiotic spectinomycin, which does not contain aminosaccharides, but has a similar structure.

Classifications of aminoglycoside antibiotics according to microbiological activity and ability to overcome acquired resistance:
– first generation: streptomycin, neomycin, kanamycin;
– second generation: gentamicin, tobramycin, netilmicin;
– third generation: amikacin.

Antibiotics – aminoglycosides exhibit a bactericidal effect, which is due to the irreversible inhibition of protein synthesis in the ribosomes of microorganisms. They have an antimicrobial effect on both resting and multiplying bacterial cells. The antimicrobial effect depends on their maximum (peak) concentration in the blood serum, i.e. aminoglycosides are concentration-dependent drugs (the higher the concentration, the stronger the antimicrobial effect). The penetration of these antibiotics into bacterial cells through the pores of the outer membrane occurs due to passive diffusion. Penetration of aminoglycosides across the cytoplasmic membrane depends on electron transfer. These processes constitute the energy-dependent stage I, which can be completely blocked by Ca 2+ or Mg 2+ ions, hyperosmolar environment, low pH and anaerobic conditions. At the second, so-called energy-dependent stage II, the structure of the cytoplasmic membrane is disrupted, aminoglycosides penetrate the microbial cell and lead to its complete destruction.

The spectrum of antimicrobial action of aminoglycosides is wide, they exhibit greater activity against gram-negative bacteria (Acinetobacter spp. , Pseudomonas spp., P. aeruginosa), less activity against gram-positive microorganisms, and practically do not affect anaerobes. Thus, aminoglycosides actively act on Escherichia coli., Proteus spp., Citrobacter spp., Enterobacter spp., Klebsiella spp., Providencia spp., Serratia spp., Salmonella spp., Shigella spp., Brucella spp., Staphylococcus aureus (except methicillin-resistant strains of S. aureus), S. Epidermidis. They do not show any activity against: Streptococcus pneumoniae, Stenotrophomonas maltophilia, Burkholderia cepacia and anaerobes (Bacteroides spp., Clostridium spp., etc.).
Used mainly to suppress gram-negative flora in the treatment of nosocomial infections, sepsis, burn infections, septic endocarditis, acute and chronic osteomyelitis, severe infections of the skin, soft tissues, respiratory tract, prevention of postoperative complications, empirical therapy (when the causative agent is unknown) . They are also prescribed for the treatment of eye infections, tuberculosis, plague, brucellosis, tularemia.